3 Questions You May Have Before Investing
1. Financial Health and Returns ?
a. Growth and Profitability:
"How is the company performing in terms of revenue growth and profitability ?"
KIC Ventures has generated over $300 million in lifetime portfolio company revenues, with over 200,000 devices implanted across the USA, Europe, Latin America, the Caribbean, and Australia. Our NANISX portfolio, introduced to Interventional Pain Management (IPM) doctors in 2020, has been profitable year-over-year and continues to grow. This track record demonstrates long-term sustainability and a proven ability to scale globally.
b. Dividends:
"Does the company plan to distribute dividends to its investors ?"
We will pay dividends when we achieve a cash infusion through an exit or when our profitability supports sustainable dividend payments.
c. Return on Investment:
"What is the anticipated timeline for investors to see a return on their investment ?"
We target 2026 for a public offering of at least one of our portfolio companies. In the meantime, we are actively engaging strategic partners and exploring opportunities to generate returns through mergers, acquisitions, or other value-driven events.
d. Investment Appreciation:
"What are the projections for valuation increases, and how might they impact my potential returns ?"
We estimate our current valuation between $1-3 billion. Given the current Series A round at a $300 million valuation, this could translate to a 3x value increase post-Series A. As we progress toward a $3 billion valuation, this would equate to a 10x return for early investors.
e. Competitive Landscape:
"What sets KIC Ventures apart in a competitive spine care market ?"
KIC Ventures is the only company with a deep portfolio of spine technologies that have entered the Interventional Pain Management (IPM) niche. Since 2019, we have gained valuable insights and built strong relationships with key opinion leaders in this emerging market. The IPM market traditionally focused on treating the symptoms of back pain. Our innovations, guided by our proprietary LESS Exposure Spine Surgery (LESS™) philosophy, introduce spine technologies designed to address the root causes of back pain, fundamentally shifting the standard of care.
We embrace a last-mover advantage, improving technologies to represent 10x advancements over existing solutions.
Our vision is to be the global leader in outpatient spine surgery, mirroring the success of interventional cardiology, plastic surgery, and dentistry. These fields have achieved significant advancements by focusing on early interventions and shifting complex treatments to outpatient settings. Similarly, KIC Ventures empowers physicians to deliver advanced outpatient spine care, improving patient outcomes while reducing reliance on hospital systems.
KIC Ventures has demonstrated resilience, grit, and an ability to prioritize investments in effective technologies and market niches. Unlike competitors who focus primarily on short-term revenue growth, we take a long-term view, investing in sustainable technologies that require continuous development. This disciplined approach ensures we remain at the forefront of innovation while creating lasting value for patients, physicians, and investors alike.
Our leadership and core team, working together for over 15 years, have a proven track record of acquiring key technologies and developing innovations that are not available for acquisition. Under the leadership of Dr. Kingsley R. Chin—a Harvard-trained orthopedic spine surgeon and entrepreneur with over 30 years of clinical and business expertise—KIC Ventures bridges clinical insight and market strategy to achieve sustainable growth.
With our deep understanding of the spine market and the needs of IPM physicians, we are uniquely positioned to scale both domestically and internationally. By combining cutting-edge technologies, cohesive leadership, and a commitment to advancing patient care, KIC Ventures delivers long-term value for investors, physicians, and patients alike.
2. Investment Details ?
a. Minimum Investment Requirement:
"What is the minimum amount required to invest in the company ?"
The minimum investment amount is $30,000.
b. Investment Benefits:
"What benefits, financial or otherwise, will I receive from my investment ?"
Investors will receive Preferred Units in KIC Ventures, with more details provided in our Investment Documents.
c. Alternative Financing Options:
"If I am currently unable to invest cash, what alternative financing options are available ?"
Options such as margin loans against stocks, credit lines, or using retirement funds (IRA/401k) are available for those without immediate cash.
3. Risks and Compliance ?
a. Investment Security:
"How does the security of this investment compare to traditional retirement or savings investments ?"
Unlike retirement funds that are subject to stock market volatility, your investment in KIC Ventures is privately held and benefits from diversification across its portfolio.
b. Regulatory Approvals:
"What is the current status and expected timeline for obtaining FDA approval for AxioMed ?"
AxioMed has submitted all necessary modules and has successfully undergone an FDA clinical data audit. The manufacturing phase, which is the last step in the approval process, is expected to take 6-9 months and can be accelerated with capital.
c. Legal Standing:
"Is KIC Ventures currently facing any legal challenges with the Department of Justice (DOJ), and how could this affect the company ?"
KIC Ventures has reached a resolution of the civil case with the government which was fully executed by all parties in November 2023, and releases the KIC Ventures entities from the DOJ civil litigation. A federal judge has dismissed money laundering charges and we are pursuing other motions. We have hired a strong legal team and focus on managing a robust compliance preventive program.
DISCLAIMER:
This presentation is subject to and conditioned upon the Investor’s (a) reviewing a Confidential Private Placement Memorandum; (b) executing a Subscription Agreement and Investor Questionnaire; (c) being qualified by the Issuer as an Accredited Investor under Regulation D. Investor shall pay no investment funds until all of the foregoing have occurred to the satisfaction of Company as the Issuer. This presentation does not take into account, nor does it provide any tax, legal or investment advice or opinion regarding the specific investment objectives or financial situation of any person. Company reserves the right to amend or replace the information contained herein, in part or entirely, at any time, and undertakes no obligation to notify the recipient thereof.